EN PL
REVIEW PAPER
The role of interleukin-1 antagonists in treatment of inflammatory disorders: current experience and perspectives
 
More details
Hide details
 
Online publication date: 2009-08-11
 
 
Reumatologia 2009;47(3):151-157
 
KEYWORDS
ABSTRACT
The interleukin-1 (IL-1) family consists of IL-1a, IL-1b, interleukin-18, and the natural inhibitor of IL-1 receptor (IL-1 Ra). The recombinant IL-1Ra, anakinra is used as anti-inflammatory agent, and was approved in 2001 for the treatment of rheumatoid arthritis (RA). Recent years have brought new data on the effectiveness of IL-1 blockade in inflammatory disorders other than RA. It has been proved that anakinra is also effective in management of diseases that are resistant to conventional medication such as systemic-onset juvenile idiopathic arthritis, adult-onset Still disease, hereditary autoinflammatory syndromes, familial Mediterranean fever or even osteoarthritis or gout. Newer approaches to IL-1 blockade, including antibodies against IL-1 are also investigated in clinical trials in patients with type 2 diabetes mellitus, and systemic-onset juvenile idiopathic arthritis. Despite the earlier moderate efficacy of anakinra in management of patients with RA, modulation of proinflammatory signaling involving IL-1 seems to be very promising in elaboration of new biological drugs for several inflammatory disorders.
 
REFERENCES (53)
1.
Ren K, Torres RK. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2009; 60: 57-64. .
 
2.
Kontny E, Maśliński W. Zaburzenia immunologiczne w patogenezie chorób reumatycznych. W: Reumatologia kliniczna. Zimmermann-Górska I (red.). T. 1. Wyd. Lek. PZWL, Warszawa 2008; 126-128. .
 
3.
Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879-896. .
 
4.
Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumor necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007; 46: 1140-1147. .
 
5.
Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology 2004; 43 (suppl. 3): iii10-iii16. .
 
6.
Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003: 42 (suppl. 2): ii3-ii10. .
 
7.
Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004; 43 (suppl. 3): ii2-ii9. .
 
8.
Eastgate JA, Symons JA, Wood NC, et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706-709. .
 
9.
Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995; 38: 642-648. .
 
10.
Dawson J, Engelhardt P, Kastelic T, et al. Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical, and histological assessment. Rheumatology (Oxford) 1999; 38: 401-406. .
 
11.
Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 1996; 93: 402-406. .
 
12.
Joosten LA, Helsen MMA, Saxne T, et al. IL1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-5055. .
 
13.
Zoń-Giebel A, Kotulska A, Giebel S i wsp. Antagonista receptora interleukiny 1 w leczeniu reumatoidalnego zapalenia stawów. Przegl Lek 2002; 59: 916-918. .
 
14.
Campion GV, Lebsack ME, Lookabaugh J, et al. Dose-range and dose-frequency study on recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39: 1092-1101. .
 
15.
Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-1009. .
 
16.
Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-624. .
 
17.
Cohen SB, Moreland LW, Cush JJ, et al. A multicenter, double-blind randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63: 1062-1068. .
 
18.
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra) in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-934. .
 
19.
den Broeder AA, de Jong E, Franssen MJ, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-762. .
 
20.
Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics of rheumatoid arthritis: a systemic review and metaanalysis. J Rheumatol 2006; 33: 2398-2408. .
 
21.
Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Databases of Syst Rev 2009 Jan 21; (1): CD005121. .
 
22.
Wailoo A, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis. The Medicare program: a cost-effectiveness. Arthritis Rheum 2008; 58: 939-946. .
 
23.
Nordstrom DC. Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions. Future Rheumatol 2007; 2: 353-360. .
 
24.
Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308. .
 
25.
Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-1486. .
 
26.
Zeft A, Hollister R, Lafleur B, et al. Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol 2009; 15: 161-164. .
 
27.
Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-137. .
 
28.
Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: A systemic review and critical analysis of the evidence. Clin Rheumatol 2008; 27: 67-76. .
 
29.
Fitzgerald AA, LeClerq SA, Homik JE, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 2005; 52: 1794-1803. .
 
30.
Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008; 22: 773-792. .
 
31.
Naglik S, Kucharz EJ. Choroba Stilla u dorosłych. Terapia 2007; 15/12: 35-37. .
 
32.
Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in ostheoarthritis of the knee: A multicenter, randomized, double-blind, placebo controlled study. Arthritis Rheum 2009; 61: 344-352. .
 
33.
So A, de Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28. .
 
34.
Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005; 64: 630-633. .
 
35.
Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from the rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008; 17: 349-59. .
 
36.
Grilo RM. New therapeutic perspective for pain relief in ostheoarthritis: anti-IL-1. Douleurs 2006; 7: 123-125. .
 
37.
Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1 beta production. Nat Acad Sci USA 2006; 103: 9982-9987. .
 
38.
Bhat A, Naguwa SM, Gershwin ME. Genetics and new treatment modalities for familial Mediterranean fever. Ann N Y Acad Sci 2007; 1110: 201-208. .
 
39.
Gattringer R, Lagler H, Gattinger KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007; 37: 912-914. .
 
40.
Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dialysis Transplant 2008; 24: 676-678. .
 
41.
Bilginer Y, Ayvaz AN, Ozen S. Anakinra for secondary amyloidosis in an adolescent with FMF and Behçet disease. Pediatr Rheumatol 2008; 6 (Suppl 1): 197. .
 
42.
Metyas SK, Hoffman HM. Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud’s disease. J Rheumatol 2006; 33: 2085-2087. .
 
43.
Hoffmann HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-1785. .
 
44.
Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-612. .
 
45.
Lovell I, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52: 1283-1286. .
 
46.
Hoffman HM, Firestein GS. Anakinra for the treatment of neonatal-onset multisystem inflammatory disease. Nat Clin Pract Rheumatol 2006; 2: 646-647. .
 
47.
Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1 beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009; 11: 81-89. .
 
48.
Larsen C, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1528. .
 
49.
Fleischmann RM, Tesser J, Schiff MH, et al. Safety extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-1012. .
 
50.
Church LD, McDermott MF. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 2008; 5: 14-15. .
 
51.
Alten R, Gram H, Joosten LA, et al. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R67. .
 
52.
Owyang AM, Vanegas S, Esposito L, et al. Efficacy of XOMA 052 anti-IL-1 beta antibody in the DBA/1 mouse collagen-induced arthritis model. Clin Immunol 2008; 127 (suppl. 1): S98-S99. .
 
53.
Donath MY, Weder C, Whitmore J, et al. XOMA 052, an anti-IL-1 beta antibody in double-blind, placebo controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus – a new approach to therapy. Diabetologia 2008; 51 (suppl. 1): S7.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top